SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is trending with its community actively discussing its multichain presence across Solana, BSC, Cronos, and ETH, highlighting a deflationary burn mechanism and positioning it as a unique meme coin poised to bring significant volume to the Cronos chain.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending after abruptly ceasing its compounded GLP-1 weight-loss pill offering following FDA warnings and legal threats, prompting a polarized community debate over whether this de-risks the company's broader telehealth platform or signifies a critical setback for its growth ambitions, further amplified by Super Bowl advertising efforts.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin ($CRO) is trending as the community discusses Trump Media's plans for digital token distribution on the Cronos chain, a new partnership for US prediction markets, and buzz around AI integration and Super Bowl advertising, all aiming to drive ecosystem adoption and associated meme coin activity.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending after strategically acquiring two new sites, effectively doubling its power and data center capacity to meet surging AI/HPC demand. The community is actively discussing its strong partnership with Google and the potential for significant upside as a key infrastructure provider, further bolstered by high short interest.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is drawing significant bullish sentiment and trading interest due to eagerly anticipated Japanese PMDA approval and promising clinical data, including strong pancreatic cancer results. The community is buzzing about its potential as an oncology breakthrough, attracting increased institutional attention.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart is seeing intense debate among investors ahead of its upcoming earnings report, with many expecting significant volatility given its AI lending model and sector-wide sentiment. While some anticipate a potential short squeeze fueled by proprietary AI data, others express frustration over management and recent market weakness in the fintech space.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending amid heightened anticipation for a Supreme Court decision on tariffs that could significantly impact its margins, alongside buzz from new "Nike Mind" products selling out and recent insider buying. The community is polarized, debating whether the stock is a deep value opportunity based on its global brand or a value trap given ongoing margin pressures and discrimination allegations.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending as its announcement of a $250 million financing amendment, extending its capital runway to 2028, sparks intense debate; bullish traders anticipate a massive short squeeze reminiscent of past parabolic moves, while skeptics raise concerns about potential dilution from the equity line of credit.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is experiencing sharp volatility amid a broader software sector sell-off, with community discussion polarized between frustration over its market underperformance and strong conviction in its undervalued AI-driven marketing technology and consistent fundamental growth, all while awaiting its upcoming earnings report.

Trump For President

TRUMP CRYPTO is trending due to heightened congressional scrutiny over foreign ties to Trump-linked digital assets, intensifying community debate on their legitimacy amidst allegations of pump-and-dump schemes and significant user losses, particularly with tokens like WLFI which feature controversial selling restrictions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Shares of Tourmaline Bio (TRML) jumped 58% in the pre-market session on Tuesday after Novartis (NVS) announced that it has agreed to acquire the smaller biopharmaceutical firm.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd">deal</a>, Novartis will commence a tender offer to purchase all outstanding shares of Tourmaline common stock through an indirect wholly owned unit. The deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price and values the company at about $1.4 billion on a fully diluted basis. Following the closing of the tender offer, the unit will merge with Tourmaline, and the company will become an indirect wholly owned subsidiary of Novartis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRML">TRML stock</a> jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> fell from ‘Neutral’ to ‘Bearish territory, while message volume rose from ‘low’ to ‘normal’ levels.Novartis stated that the acquisition includes Tourmaline’s Pacibekitug being developed as a treatment option for atherosclerotic cardiovascular disease or the build-up of fats, cholesterol, and other substances in and on the artery walls. Pacibekitug complements Novartis’ cardiovascular strategy, the company said, while noting that with mid-stage trials of Pacibekitug already well-advanced, the company will acquire a late-stage-ready asset."Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring Pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," said Shreeram Aradhye, Chief Medical Officer of Novartis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The transaction has been unanimously approved by the Board of Directors of both companies. It is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions. Until the transaction is closed, the two companies will continue to operate as separate, independent entities, Novartis said.TRML stock is up by 49% this year, while NVS stock gained over 32%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-launches-ai-machine-learning-platform-called-tunelab/chwKTzARdsU">Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 

Equity

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 


Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's  What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

Tourmaline Bio Inc

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

TRML
Tourmaline Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TRML News

TRMLTourmaline Bio Inc